Drugs / HDCV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06546709 | Jan 2025 → May 2026 overdue | Lassa fever | Wilbur Chen, MD, MS | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546709 ↗ |